A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

Bioequivalence Clinical Trial

Official title:

A Randomized, Open-label, Two-preparation, Single-dose, Two-sequence Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04993222
• Other study ID #: HC1507YBE201901
• Status: Completed
• Phase: Phase 1
• Start date: June 4, 2020
• Est. completion date: November 16, 2020

Study information

• Verified date: July 2021
• Source: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The 2 × 2 crossover designed study is to evaluate the bioequivalence of two different amphotericin B liposome for injection after single IV infusion at the same dose in normal healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: November 16, 2020
• Est. primary completion date: September 8, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign informed consent.

2. Healthy female and male volunteers aged 18-55 years.

3. Body weight = 50 kg for male and = 45 kg for female with a body mass index (BMI) in the range of 19.0 to 26.0 kg/m2 (inclusive).

4. Subjects must be in good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.

5. Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion Criteria:

1. History of allergic reactions to amphotericin B or its analogs. History of allergy to two or more kinds of drugs or food.

2. Subjects have any history of surgery, trauma that may affect the safety of the study or the intracorporal process of the drug, or have a surgical schedule during the study period.

3. Use of any prescription or over the counter medication within 14 days prior to screening.

4. History of drug abuse within 6 months prior to screening.

5. Smoking more than 5 cigarettes per day within 3 months prior to screening, or unable to stop using any tobacco products during the trial period.

6. Consumption of alcohol in excess of 14 units/week within 3 months prior to screening.

7. Consumption excessive amounts of tea, coffee and/or caffeine-rich beverages daily within 3 months prior to screening.

8. Participation in other trial within 3 months prior to screening.

9. Donation or loss of more than 400 mL blood within 3 months prior to screening.

10. Subject (female) is lactating or pregnant.

11. Subject who cannot tolerate venipuncture or have a history of needle and blood sickness.

12. Subject who has special requirements on diet and cannot accept the uniform diet.

13. Subject who has childbearing plan, unwillingness or inability to use effective contraceptives from 2 weeks before the screening to 6 months after the last dosing of the study drug.

14. Any positive test result for Hepatitis B surface antigen, hepatitis C virus antibody, anti-human immunodeficiency virus antibody or anti-syphilis spirochete.

15. Female subjects with positive pregnancy test results during the screening period or during the study.

16. Positive test result for alcohol screening or drug abuse.

17. AST or ALT, total or direct bilirubin, alkaline phosphatase and creatinine are above the upper limit of normal and potassium is below the lower limit of normal; any other abnormalities in laboratory tests and ancillary tests that are judged by the investigator to be clinically significant.

18. Not suitable for this study as determined by the investigator due to other reasons.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• Amphotericin B liposome for injection
IV infusion
• AmBisome®
IV infusion

Locations

Country	Name	City	State
China	Wuhan Medical Treatment Center	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bioequivalence based on Cmax	90% CI of Cmax of liposome-encapsulated and non-liposome-encapsulated Amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%~125.00%.	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Primary	Bioequivalence based on AUC0-t	90% CI of AUC0-t of liposome-encapsulated andnon-liposome-encapsulated Amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%~125.00%.	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Primary	Bioequivalence based on AUCinf	90% CI of AUC0-8 of liposome-encapsulated and non-liposome-encapsulated Amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%~125.00%.	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Secondary	Tmax of liposome-encapsulated and non-liposome-encapsulated Amphotericin B	Time of maximum observed concentration	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Secondary	t1/2 of liposome-encapsulated and non-liposome-encapsulated Amphotericin B	Terminal elimination half-life	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Secondary	?z of liposome-encapsulated and non-liposome-encapsulated Amphotericin B	Apparent elimination rate constant	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Secondary	Residual area of liposome-encapsulated and non-liposome-encapsulated Amphotericin B	Extrapolated area	predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion
Secondary	Number of treatment-emergent adverse events for the test and the reference products		predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion